P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

Autor: M Mateos, M Szarejko, J Bila, F Schjesvold, I Spicka, V Maisnar, A Jurczyszyn, Z Grudeva-Popova, R Hajek, G Usenko, M Thuresson, S Norin, S Jarefors, P Richardson, L Pour

Publikováno v: HemaSphere, Vol 7, Iss S2, Pp 29-30 (2023)

Externí odkaz: https://doaj.org/article/1429889200b14aa1b21a44565a7d7434

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma.

Autor: Knop S; Universitätsklinikum Würzburg Würzburg Germany., Szarejko M; Uniwersyteckie Centrum Kliniczne Gdansk Poland., Grząśko N; Department of Experimental Hematooncology Medical University of Lublin and Centrum Onkologii Ziemi Lubelskiej Lublin Poland., Bringhen S; SSD Clinical Trial in Oncoematologia e Myeloma, Dipartimento di Oncologia Azienda Ospedaliera-Universitaria Città della Salute e della Scienza di Torino Torino Italy., Trautmann-Grill K; Universitätsklinikum Dresden, Technische Universität Dresden Dresden Germany., Jurczyszyn A; Plasma Cell Dyscrasias Center, Department of Hematology Jagiellonian University Medical College Krakow Poland., Vacca A; Department of Precision and Regenerative Medicine and Ionian Area Unit of Medicina Interna 'Guido Baccelli' University of Bari Aldo Moro Azienda Policlinico Bari Italy., Khandanpour C; Universitätsklinikum Münster, Münster, Germany and University Hospital Schleswig-Holstein Campus Lübeck University Cancer Center Schleswig-Holstein, and University of Lübeck Lübeck Germany., Gamberi B; AUSL-IRCCS Reggio Emilia Reggio Emilia Italy., Pour L; Fakultní Nemocnice Brno Brno Czechia., Iversen KF; Lillebaelt Hospital Vejle Denmark., Stumpp MT; Molecular Partners AG Zurich-Schlieren Switzerland., Suter C; Molecular Partners AG Zurich-Schlieren Switzerland., Dawson KM; Molecular Partners AG Zurich-Schlieren Switzerland., Zitt C; Molecular Partners AG Zurich-Schlieren Switzerland., Legenne P; Molecular Partners AG Zurich-Schlieren Switzerland., Stavropoulou V; Molecular Partners AG Zurich-Schlieren Switzerland., Fey MF; Molecular Partners AG Zurich-Schlieren Switzerland., Leupin N; Molecular Partners AG Zurich-Schlieren Switzerland., Goldschmidt H; Medical Department V Universitätsklinikum Heidelberg Heidelberg Germany.

Publikováno v: EJHaem [EJHaem] 2024 Aug 01; Vol. 5 (5), pp. 940-950. Date of Electronic Publication: 2024 Aug 01 (Print Publication: 2024).